Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

Contact Lens Discomfort Clinical Trial

Official title:

A Controlled Phase 2 Study for Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03994406
• Other study ID #: CLM-1
• Status: Completed
• Phase: Phase 2
• Start date: June 27, 2019
• Est. completion date: October 30, 2019

Study information

• Verified date: March 2023
• Source: Glia, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study compares contact lens comfortable wear duration, and signs and symptoms of contact lens discomfort, test versus control.

Description:

The clinical hypothesis is that CLM2 topical gel applied dermally on the forehead twice daily will be more effective than placebo (a) in reducing or eliminating ocular discomfort associated with contact lens wear, (b) prolong hours of comfortable wear, (c) prolong total hours of contact lens wear, (d) improve ease of insertion and removal of contact lens, and ( c) reduces friction between cornea/lens and lens/eyelid, without use of artificial eye drops or gels. One mechanism supporting this hypothesis is preliminary evidence of increased meibum secretion following CLM2 topical gel application.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 30, 2019
• Est. primary completion date: August 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female of any race =18 years of age at Visit 1 Screening.

2. Has provided verbal and written informed consent.

3. Be able and willing to follow instructions, including participation in all study assessments and visits.

4. Has been wearing soft contact lens in both eyes at least 2 days per week for at least a month.

5. Duration of comfortable lens wear daily is less than desired.

6. Suffers from at least two other symptoms while wearing lens with contact lens discomfort of grade 2 or higher:

1. Dryness.

2. Grittiness

3. Blurred vision

4. Itching

5. Conjunctival redness

6. Burning

7. Stinging.

8. Lens awareness

9. Use of artificial tears or gels two or more times a day during contact lens wear hours.

7. Berkeley Dry Eye Flow Chart (DEFC) score =3.

Exclusion Criteria:

1. BCVA at baseline <20/40.

2. Wearing contact lens only in one eye.

3. Wearers of the following contact lenses: Extended wear, prosthetic, scleral, and intracorneal gas permeable.

4. Pregnant women or women of childbearing potential who are not using contraception.

5. Diagnosis of the following autoimmune diseases: Addison's disease, Grave's disease, Hashimoto's thyroiditis, lupus, and Sjogren's syndrome.

6. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such dystrophies, infections, etc.

7. Has a condition or be in a situation that, the opinion of the investigator, that may interfere significantly with the subject's participation in the study. No active ocular condition or disease.

8. Has a known adverse reaction and/or sensitivity to either study drug or its components.

9. Unwilling to remove contact lens overnight.

10. Unwilling to attempt to wear contact lens seven (7) days a week during the study period.

11. Plan to change brand of contact lens during study period.

12. Unwilling to wear contact lens for at least 10 hours if comfort permits, or until discomfort requires removal of contact lens prior to 10 hours.

13. Unwilling to discontinue swimming with immersed head for the duration of the study.

14. Unwilling to withhold the use of artificial tears, gels, or wetting agents during periods when contact lens is worn during the study period.

15. Cannot withhold the following medications during the study period:

antihistamines, some diuretics, antidepressants, antipsychotics, Restasis, Xiidra, Accutane, glaucoma medications, other anti-cholinergics; as well as gabapentin.

16. Currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1.

Related Conditions & MeSH terms

• Contact Lens Acute Red Eye
• Contact Lens Discomfort
• Contact Lens-induced Corneal Disorder
• Contact Lens-induced Corneal Fluorescein Staining
• Corneal Diseases

Intervention

Drug:
• CLM2 topical gel
Active topical gel for forehead dermal application
• Placebo topical gel
Placebo topical gel for forehead dermal application

Locations

Country	Name	City	State
United States	UC Berkeley Clinical Research Center	Berkeley	California

Sponsors (1)

Lead Sponsor	Collaborator
Glia, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hours of continuous comfortable contact lens wear	Change in total hours per day	21 days
Primary	Contact Lens Questionnaire-8 (CLDEQ-8)	Change in total score (0-37 worst)	21 days
Primary	Berkeley Dry Eye Flow Chart	Change in grade (1-5 worst)	21 days
Primary	Fluorescein corneal staining	Change in score (0-3 worst)	21 days
Secondary	Eye discomfort from CLDEQ-8, frequency	Change in score (0-4 worst)	21 days
Secondary	Eye discomfort from CLDEQ-8, intensity	Change in score (0-5 worst)	21 days
Secondary	Glia contact lens symptoms questionnaire	Change in total score (0-64)	21 days
Secondary	Fluorescein conjunctival staining	Change in conjunctival staining (0-3 worst)	21 days
Secondary	Tear film examination by TearScan	Change in total score (0-3 best)	60-80 minutes
Secondary	Tear film examination by TearScan	Change in total score (0-3 best)	21 days
Secondary	Tear film breakup time	Change in score (seconds)	60-80 minutes
Secondary	Tear film breakup time	Change in score (seconds)	21 days
Secondary	Tear meniscus height	Change in height (mm)	60-80 minutes
Secondary	Tear meniscus height	Change in height (mm)	21 days
Secondary	Visual acuity	Change in visual acuity	21 days
Secondary	Tear osmolarity	Change in tear osmolarity (mOsm/L)	21 days
Secondary	Schirmer test	Change in wetting length (mm)	21 days